Skip to main content
This site is intended for US Healthcare Professionals only
Find MF-CICL Logo
This site is intended for US Healthcare Professionals only

Evaluating MF-CTCL requires a combination of clinical findings and pathologic criteria1,2

Evaluating MF-CTCL Evaluating MF-CTCL
  • Clinical examination, skin biopsy, and bloodwork are necessary for diagnosis2
  • Other screening tests such as a CT or PET scan may be indicated, depending on the patient’s history3

NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) recommended laboratory tests for MF-CTCL2:

  • Complete blood count (CBC) with Sézary screen
  • Sézary flow cytometric study (optional for T1)
  • Dermatopathology review of slides
  • Clonal T-cell receptor gene (TCR) rearrangement of peripheral blood lymphocytes (as assessed by polymerase chain reaction [PCR]) if blood involvement is suspected
  • Comprehensive metabolic panel
  • Lactate dehydrogenase (LDH)
  • Pregnancy testing women of child-bearing age

Unresponsive or recurrent lesions may be a reason to biopsy for MF-CTCL2


  1. Song SX, Willemze R, Swerdlow SH, Kinney MC, Said JW. Mycosis fungoides: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol. 2013;139(4):466-490.
  2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Primary Cutaneous Lymphomas V.2.2019. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed December 17, 2018. To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  3. Cutaneous Lymphoma Foundation. Mycosis fungoides. Cutaneous Lymphoma Foundation website. Accessed January 14, 2019.